Goldman Sachs’s ENDRA Life Sciences NDRA Stock Holding History

Goldman Sachs’s Portfolio NDRA Stock Details NDRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1	Closed	-$104K	–	6418
2021 Q2	$104K	Buy	+1	New	+$78.7K	﹤0.01%	5935

Other funds holding NDRA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

55I LLC Boston, Massachusetts $3.58B AUM 17.97% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Goldman Sachs's NDRA Position: Q3 2021 in Review

Goldman Sachs sold out of ENDRA Life Sciences (NDRA) in Q3 2021, closing a stake of 1 share — an estimated $104K sold.

Goldman Sachs first reported a position in NDRA in Q2 2021 and held it in 1 quarter. The position peaked at $104K in Q2 2021. 11 funds tracked by Wall St. Rank hold NDRA as of Q3 2021.

Goldman Sachs reported no remaining ENDRA Life Sciences position as of Q3 2021 after selling out during the quarter.
Goldman Sachs sold 1 ENDRA Life Sciences share in Q3 2021, an estimated $104K.
Goldman Sachs first reported a position in ENDRA Life Sciences in Q2 2021 and held it in 1 quarter.
Goldman Sachs's ENDRA Life Sciences position peaked at $104K in Q2 2021.
11 funds tracked by Wall St. Rank held ENDRA Life Sciences as of Q3 2021.

Based on Goldman Sachs's 13F filing for Q3 2021, filed 10 Nov 2021.